nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—ABCG2—Dactinomycin—ocular cancer	0.159	0.36	CbGbCtD
Sorafenib—ABCC2—Carboplatin—ocular cancer	0.118	0.268	CbGbCtD
Sorafenib—ABCG2—Carboplatin—ocular cancer	0.107	0.242	CbGbCtD
Sorafenib—ABCB1—Dactinomycin—ocular cancer	0.0574	0.13	CbGbCtD
Sorafenib—Radiation recall reaction (dermatologic)—Dactinomycin—ocular cancer	0.00526	0.186	CcSEcCtD
Sorafenib—Recall phenomenon—Dactinomycin—ocular cancer	0.00498	0.176	CcSEcCtD
Sorafenib—ZAK—eye—ocular cancer	0.0032	0.0397	CbGeAlD
Sorafenib—HIPK3—retina—ocular cancer	0.00311	0.0385	CbGeAlD
Sorafenib—EPHX2—eye—ocular cancer	0.00269	0.0332	CbGeAlD
Sorafenib—TIE1—epithelium—ocular cancer	0.00268	0.0332	CbGeAlD
Sorafenib—EPHX2—retina—ocular cancer	0.00266	0.0329	CbGeAlD
Sorafenib—CDK7—lymphoid tissue—ocular cancer	0.00261	0.0323	CbGeAlD
Sorafenib—FLT4—eye—ocular cancer	0.00242	0.03	CbGeAlD
Sorafenib—ZAK—lymphoid tissue—ocular cancer	0.00226	0.0279	CbGeAlD
Sorafenib—MAP3K7—retina—ocular cancer	0.00224	0.0277	CbGeAlD
Sorafenib—FLT4—epithelium—ocular cancer	0.00222	0.0274	CbGeAlD
Sorafenib—MKNK2—eye—ocular cancer	0.00219	0.0271	CbGeAlD
Sorafenib—MKNK2—retina—ocular cancer	0.00217	0.0269	CbGeAlD
Sorafenib—MKNK1—eye—ocular cancer	0.00216	0.0268	CbGeAlD
Sorafenib—MKNK1—retina—ocular cancer	0.00215	0.0265	CbGeAlD
Sorafenib—MKNK2—epithelium—ocular cancer	0.00201	0.0248	CbGeAlD
Sorafenib—RALBP1—eye—ocular cancer	0.00198	0.0245	CbGeAlD
Sorafenib—RALBP1—retina—ocular cancer	0.00196	0.0243	CbGeAlD
Sorafenib—RET—epithelium—ocular cancer	0.00196	0.0242	CbGeAlD
Sorafenib—Ascites—Dactinomycin—ocular cancer	0.0019	0.0672	CcSEcCtD
Sorafenib—FLT1—eye—ocular cancer	0.00188	0.0233	CbGeAlD
Sorafenib—FLT3—lymphoid tissue—ocular cancer	0.00188	0.0232	CbGeAlD
Sorafenib—RAF1—eye—ocular cancer	0.00187	0.0232	CbGeAlD
Sorafenib—FLT1—retina—ocular cancer	0.00187	0.0231	CbGeAlD
Sorafenib—FLT1—epithelium—ocular cancer	0.00172	0.0213	CbGeAlD
Sorafenib—RAF1—epithelium—ocular cancer	0.00171	0.0212	CbGeAlD
Sorafenib—FLT4—lymphoid tissue—ocular cancer	0.00171	0.0211	CbGeAlD
Sorafenib—KDR—eye—ocular cancer	0.00159	0.0197	CbGeAlD
Sorafenib—KDR—retina—ocular cancer	0.00158	0.0195	CbGeAlD
Sorafenib—CSF1R—eye—ocular cancer	0.00155	0.0192	CbGeAlD
Sorafenib—MKNK2—lymphoid tissue—ocular cancer	0.00154	0.0191	CbGeAlD
Sorafenib—MKNK1—lymphoid tissue—ocular cancer	0.00153	0.0189	CbGeAlD
Sorafenib—RET—lymphoid tissue—ocular cancer	0.00151	0.0186	CbGeAlD
Sorafenib—KDR—epithelium—ocular cancer	0.00146	0.018	CbGeAlD
Sorafenib—PDGFRB—eye—ocular cancer	0.00138	0.0171	CbGeAlD
Sorafenib—Folliculitis—Dactinomycin—ocular cancer	0.00137	0.0486	CcSEcCtD
Sorafenib—FLT1—lymphoid tissue—ocular cancer	0.00133	0.0164	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—ocular cancer	0.00132	0.0163	CbGeAlD
Sorafenib—KIT—epithelium—ocular cancer	0.00129	0.016	CbGeAlD
Sorafenib—PDGFRB—epithelium—ocular cancer	0.00126	0.0156	CbGeAlD
Sorafenib—STK10—lymphoid tissue—ocular cancer	0.00126	0.0155	CbGeAlD
Sorafenib—PDGFRA—lymphoid tissue—ocular cancer	0.00124	0.0154	CbGeAlD
Sorafenib—KDR—lymphoid tissue—ocular cancer	0.00112	0.0139	CbGeAlD
Sorafenib—CSF1R—lymphoid tissue—ocular cancer	0.00109	0.0135	CbGeAlD
Sorafenib—KIT—lymphoid tissue—ocular cancer	0.000994	0.0123	CbGeAlD
Sorafenib—PDGFRB—lymphoid tissue—ocular cancer	0.000971	0.012	CbGeAlD
Sorafenib—Hypocalcaemia—Dactinomycin—ocular cancer	0.000944	0.0334	CcSEcCtD
Sorafenib—Infection—Carboplatin—ocular cancer	0.000825	0.0292	CcSEcCtD
Sorafenib—Mouth ulceration—Dactinomycin—ocular cancer	0.000781	0.0276	CcSEcCtD
Sorafenib—Pain—Carboplatin—ocular cancer	0.00071	0.0251	CcSEcCtD
Sorafenib—Hepatic failure—Dactinomycin—ocular cancer	0.000698	0.0247	CcSEcCtD
Sorafenib—Body temperature increased—Carboplatin—ocular cancer	0.000656	0.0232	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Dactinomycin—ocular cancer	0.000565	0.02	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Dactinomycin—ocular cancer	0.000565	0.02	CcSEcCtD
Sorafenib—Dysphagia—Dactinomycin—ocular cancer	0.000542	0.0192	CcSEcCtD
Sorafenib—Neutropenia—Dactinomycin—ocular cancer	0.000507	0.0179	CcSEcCtD
Sorafenib—CYP2B6—lymphoid tissue—ocular cancer	0.000503	0.00623	CbGeAlD
Sorafenib—Pneumonia—Dactinomycin—ocular cancer	0.000486	0.0172	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Dactinomycin—ocular cancer	0.000479	0.0169	CcSEcCtD
Sorafenib—Stomatitis—Dactinomycin—ocular cancer	0.000471	0.0167	CcSEcCtD
Sorafenib—Erythema multiforme—Dactinomycin—ocular cancer	0.00041	0.0145	CcSEcCtD
Sorafenib—Flushing—Dactinomycin—ocular cancer	0.000403	0.0142	CcSEcCtD
Sorafenib—Alopecia—Dactinomycin—ocular cancer	0.000383	0.0136	CcSEcCtD
Sorafenib—ABCB1—retina—ocular cancer	0.000378	0.00468	CbGeAlD
Sorafenib—Erythema—Dactinomycin—ocular cancer	0.000378	0.0134	CcSEcCtD
Sorafenib—ABCB1—epithelium—ocular cancer	0.000349	0.00432	CbGeAlD
Sorafenib—Anaemia—Dactinomycin—ocular cancer	0.000349	0.0123	CcSEcCtD
Sorafenib—Leukopenia—Dactinomycin—ocular cancer	0.000338	0.012	CcSEcCtD
Sorafenib—Myalgia—Dactinomycin—ocular cancer	0.000321	0.0114	CcSEcCtD
Sorafenib—Infection—Dactinomycin—ocular cancer	0.000306	0.0108	CcSEcCtD
Sorafenib—Thrombocytopenia—Dactinomycin—ocular cancer	0.000302	0.0107	CcSEcCtD
Sorafenib—Anorexia—Dactinomycin—ocular cancer	0.000294	0.0104	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dactinomycin—ocular cancer	0.000281	0.00993	CcSEcCtD
Sorafenib—ABCB1—lymphoid tissue—ocular cancer	0.000269	0.00333	CbGeAlD
Sorafenib—Decreased appetite—Dactinomycin—ocular cancer	0.000268	0.00947	CcSEcCtD
Sorafenib—Fatigue—Dactinomycin—ocular cancer	0.000266	0.00939	CcSEcCtD
Sorafenib—Pain—Dactinomycin—ocular cancer	0.000264	0.00932	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dactinomycin—ocular cancer	0.000252	0.00891	CcSEcCtD
Sorafenib—Abdominal pain—Dactinomycin—ocular cancer	0.000244	0.00861	CcSEcCtD
Sorafenib—Body temperature increased—Dactinomycin—ocular cancer	0.000244	0.00861	CcSEcCtD
Sorafenib—Hypersensitivity—Dactinomycin—ocular cancer	0.000227	0.00803	CcSEcCtD
Sorafenib—Asthenia—Dactinomycin—ocular cancer	0.000221	0.00782	CcSEcCtD
Sorafenib—Diarrhoea—Dactinomycin—ocular cancer	0.000211	0.00746	CcSEcCtD
Sorafenib—Vomiting—Dactinomycin—ocular cancer	0.000196	0.00693	CcSEcCtD
Sorafenib—Rash—Dactinomycin—ocular cancer	0.000194	0.00687	CcSEcCtD
Sorafenib—Nausea—Dactinomycin—ocular cancer	0.000183	0.00647	CcSEcCtD
Sorafenib—MAPK11—Gene Expression—MYC—ocular cancer	1.86e-05	4.15e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—HRAS—ocular cancer	1.86e-05	4.14e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN2B—ocular cancer	1.85e-05	4.12e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—HRAS—ocular cancer	1.85e-05	4.11e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GNA11—ocular cancer	1.85e-05	4.11e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CDKN1B—ocular cancer	1.84e-05	4.1e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—EP300—ocular cancer	1.84e-05	4.1e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MDM2—ocular cancer	1.84e-05	4.09e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—EP300—ocular cancer	1.84e-05	4.09e-05	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—AKT1—ocular cancer	1.83e-05	4.08e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—AKT1—ocular cancer	1.83e-05	4.07e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CCND1—ocular cancer	1.8e-05	4.01e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—EP300—ocular cancer	1.79e-05	3.99e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CDKN1A—ocular cancer	1.79e-05	3.98e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CDKN1A—ocular cancer	1.78e-05	3.97e-05	CbGpPWpGaD
Sorafenib—CDK7—Gene Expression—AKT1—ocular cancer	1.77e-05	3.94e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CCND1—ocular cancer	1.76e-05	3.91e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	1.75e-05	3.89e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CDKN1A—ocular cancer	1.74e-05	3.88e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—ocular cancer	1.74e-05	3.87e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CDKN1B—ocular cancer	1.74e-05	3.87e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CDKN1A—ocular cancer	1.74e-05	3.87e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MDM2—ocular cancer	1.73e-05	3.86e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HRAS—ocular cancer	1.73e-05	3.86e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—AKT1—ocular cancer	1.73e-05	3.86e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MDM2—ocular cancer	1.72e-05	3.82e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GNAQ—ocular cancer	1.72e-05	3.82e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—AKT1—ocular cancer	1.72e-05	3.82e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—MYC—ocular cancer	1.71e-05	3.82e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—TGFB1—ocular cancer	1.71e-05	3.81e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CDKN1A—ocular cancer	1.7e-05	3.78e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EP300—ocular cancer	1.7e-05	3.78e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—AKT1—ocular cancer	1.7e-05	3.78e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—E2F1—ocular cancer	1.7e-05	3.78e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MDM2—ocular cancer	1.7e-05	3.78e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EP300—ocular cancer	1.69e-05	3.77e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CDKN1B—ocular cancer	1.68e-05	3.74e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—HRAS—ocular cancer	1.66e-05	3.7e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HRAS—ocular cancer	1.66e-05	3.7e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EP300—ocular cancer	1.66e-05	3.69e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EP300—ocular cancer	1.65e-05	3.68e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GNA11—ocular cancer	1.65e-05	3.67e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—AKT1—ocular cancer	1.65e-05	3.67e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—AKT1—ocular cancer	1.64e-05	3.65e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—AKT1—ocular cancer	1.63e-05	3.63e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EP300—ocular cancer	1.62e-05	3.6e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GNA11—ocular cancer	1.61e-05	3.58e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CDKN1A—ocular cancer	1.6e-05	3.57e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CDKN1B—ocular cancer	1.58e-05	3.53e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CDKN1B—ocular cancer	1.57e-05	3.49e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MDM2—ocular cancer	1.56e-05	3.48e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MDM2—ocular cancer	1.56e-05	3.48e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MYC—ocular cancer	1.56e-05	3.47e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—ocular cancer	1.56e-05	3.47e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CDKN1B—ocular cancer	1.55e-05	3.45e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CDKN1A—ocular cancer	1.55e-05	3.45e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GNAQ—ocular cancer	1.53e-05	3.41e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—AKT1—ocular cancer	1.53e-05	3.4e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EP300—ocular cancer	1.53e-05	3.4e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GNA11—ocular cancer	1.52e-05	3.38e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCND1—ocular cancer	1.51e-05	3.36e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GNA11—ocular cancer	1.5e-05	3.35e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCND1—ocular cancer	1.5e-05	3.33e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GNAQ—ocular cancer	1.5e-05	3.33e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MDM2—ocular cancer	1.48e-05	3.3e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MYC—ocular cancer	1.48e-05	3.3e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MDM2—ocular cancer	1.48e-05	3.3e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—ocular cancer	1.48e-05	3.29e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MYC—ocular cancer	1.48e-05	3.29e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EP300—ocular cancer	1.47e-05	3.28e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—ocular cancer	1.47e-05	3.28e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HRAS—ocular cancer	1.47e-05	3.28e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—AKT1—ocular cancer	1.47e-05	3.27e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—AKT1—ocular cancer	1.47e-05	3.27e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CDKN1A—ocular cancer	1.46e-05	3.25e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CDKN1A—ocular cancer	1.45e-05	3.22e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MYC—ocular cancer	1.45e-05	3.22e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—ocular cancer	1.44e-05	3.21e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CDKN1A—ocular cancer	1.43e-05	3.18e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CDKN1B—ocular cancer	1.43e-05	3.18e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CDKN1B—ocular cancer	1.43e-05	3.18e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GNAQ—ocular cancer	1.41e-05	3.14e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MYC—ocular cancer	1.41e-05	3.14e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—ocular cancer	1.41e-05	3.13e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GNAQ—ocular cancer	1.4e-05	3.11e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EP300—ocular cancer	1.39e-05	3.1e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—ocular cancer	1.39e-05	3.08e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EP300—ocular cancer	1.38e-05	3.07e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCND1—ocular cancer	1.36e-05	3.03e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCND1—ocular cancer	1.36e-05	3.03e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EP300—ocular cancer	1.36e-05	3.03e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CDKN1B—ocular cancer	1.36e-05	3.02e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CDKN1B—ocular cancer	1.35e-05	3.01e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—HRAS—ocular cancer	1.35e-05	3e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MDM2—ocular cancer	1.33e-05	2.97e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MYC—ocular cancer	1.33e-05	2.96e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—ocular cancer	1.33e-05	2.96e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—HRAS—ocular cancer	1.33e-05	2.95e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HRAS—ocular cancer	1.33e-05	2.95e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CDKN1A—ocular cancer	1.32e-05	2.93e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CDKN1A—ocular cancer	1.32e-05	2.93e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—AKT1—ocular cancer	1.3e-05	2.89e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCND1—ocular cancer	1.29e-05	2.88e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—AKT1—ocular cancer	1.29e-05	2.88e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCND1—ocular cancer	1.29e-05	2.87e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GNA11—ocular cancer	1.28e-05	2.86e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MDM2—ocular cancer	1.27e-05	2.83e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—ocular cancer	1.26e-05	2.8e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—ocular cancer	1.26e-05	2.8e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EP300—ocular cancer	1.25e-05	2.79e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EP300—ocular cancer	1.25e-05	2.79e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CDKN1A—ocular cancer	1.25e-05	2.78e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CDKN1A—ocular cancer	1.25e-05	2.78e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—ocular cancer	1.24e-05	2.75e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—ocular cancer	1.23e-05	2.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CDKN1B—ocular cancer	1.22e-05	2.71e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MYC—ocular cancer	1.21e-05	2.7e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—ocular cancer	1.21e-05	2.69e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MYC—ocular cancer	1.2e-05	2.67e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—ocular cancer	1.2e-05	2.67e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GNAQ—ocular cancer	1.19e-05	2.66e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EP300—ocular cancer	1.19e-05	2.65e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—AKT1—ocular cancer	1.19e-05	2.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MDM2—ocular cancer	1.19e-05	2.65e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—ocular cancer	1.19e-05	2.64e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EP300—ocular cancer	1.19e-05	2.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MYC—ocular cancer	1.19e-05	2.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—ocular cancer	1.18e-05	2.63e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—ocular cancer	1.18e-05	2.63e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—AKT1—ocular cancer	1.17e-05	2.61e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AKT1—ocular cancer	1.17e-05	2.61e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—EP300—ocular cancer	1.17e-05	2.61e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—EP300—ocular cancer	1.17e-05	2.61e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—ocular cancer	1.16e-05	2.59e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCND1—ocular cancer	1.16e-05	2.59e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1B—ocular cancer	1.16e-05	2.59e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—ocular cancer	1.16e-05	2.58e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—ocular cancer	1.16e-05	2.58e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—ocular cancer	1.15e-05	2.56e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—ocular cancer	1.14e-05	2.53e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—ocular cancer	1.13e-05	2.52e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—ocular cancer	1.13e-05	2.51e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CDKN1A—ocular cancer	1.12e-05	2.5e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—ocular cancer	1.11e-05	2.48e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—ocular cancer	1.11e-05	2.47e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—ocular cancer	1.11e-05	2.47e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—ocular cancer	1.11e-05	2.46e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—ocular cancer	1.1e-05	2.46e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—ocular cancer	1.09e-05	2.43e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—ocular cancer	1.09e-05	2.43e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—ocular cancer	1.09e-05	2.43e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—ocular cancer	1.09e-05	2.43e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1B—ocular cancer	1.09e-05	2.42e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—ocular cancer	1.08e-05	2.41e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1A—ocular cancer	1.07e-05	2.39e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EP300—ocular cancer	1.07e-05	2.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—ocular cancer	1.05e-05	2.33e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—ocular cancer	1.04e-05	2.32e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—ocular cancer	1.04e-05	2.31e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—ocular cancer	1.04e-05	2.31e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—ocular cancer	1.03e-05	2.3e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—ocular cancer	1.03e-05	2.3e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—ocular cancer	1.03e-05	2.3e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—ocular cancer	1.03e-05	2.29e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MDM2—ocular cancer	1.03e-05	2.28e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—ocular cancer	1.02e-05	2.28e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EP300—ocular cancer	1.02e-05	2.27e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—ocular cancer	1.01e-05	2.25e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—ocular cancer	1e-05	2.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1A—ocular cancer	1e-05	2.23e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—ocular cancer	9.99e-06	2.23e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—ocular cancer	9.95e-06	2.22e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—EP300—ocular cancer	9.94e-06	2.21e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNA11—ocular cancer	9.91e-06	2.21e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—ocular cancer	9.86e-06	2.19e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—EP300—ocular cancer	9.85e-06	2.19e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—ocular cancer	9.77e-06	2.18e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—ocular cancer	9.75e-06	2.17e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—ocular cancer	9.63e-06	2.15e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—ocular cancer	9.53e-06	2.12e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EP300—ocular cancer	9.53e-06	2.12e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—ocular cancer	9.52e-06	2.12e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—ocular cancer	9.43e-06	2.1e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1B—ocular cancer	9.37e-06	2.09e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—ocular cancer	9.32e-06	2.07e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—ocular cancer	9.31e-06	2.07e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—ocular cancer	9.29e-06	2.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—ocular cancer	9.27e-06	2.06e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—ocular cancer	9.23e-06	2.05e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNAQ—ocular cancer	9.21e-06	2.05e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—ocular cancer	8.97e-06	2e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—ocular cancer	8.97e-06	2e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—ocular cancer	8.94e-06	1.99e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—ocular cancer	8.91e-06	1.98e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—ocular cancer	8.89e-06	1.98e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—ocular cancer	8.86e-06	1.97e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1A—ocular cancer	8.65e-06	1.92e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—ocular cancer	8.58e-06	1.91e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—ocular cancer	8.58e-06	1.91e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—ocular cancer	8.52e-06	1.9e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—ocular cancer	8.49e-06	1.89e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—ocular cancer	8.42e-06	1.87e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—ocular cancer	8.4e-06	1.87e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—ocular cancer	8.32e-06	1.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—ocular cancer	8.3e-06	1.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—ocular cancer	8.28e-06	1.84e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EP300—ocular cancer	8.23e-06	1.83e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—ocular cancer	8.22e-06	1.83e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—ocular cancer	8.14e-06	1.81e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—ocular cancer	8.12e-06	1.81e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—ocular cancer	7.65e-06	1.7e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—ocular cancer	7.58e-06	1.69e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—ocular cancer	7.58e-06	1.69e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—ocular cancer	7.32e-06	1.63e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—ocular cancer	7.3e-06	1.62e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—EP300—ocular cancer	7.29e-06	1.62e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—ocular cancer	7.19e-06	1.6e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—ocular cancer	7.17e-06	1.6e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—ocular cancer	7.17e-06	1.6e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—ocular cancer	7.15e-06	1.59e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—EP300—ocular cancer	7.12e-06	1.59e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—ocular cancer	7.08e-06	1.58e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—ocular cancer	7.08e-06	1.58e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—ocular cancer	6.98e-06	1.55e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—ocular cancer	6.82e-06	1.52e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—ocular cancer	6.52e-06	1.45e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—ocular cancer	6.46e-06	1.44e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—EP300—ocular cancer	6.17e-06	1.37e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—ocular cancer	6.16e-06	1.37e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—ocular cancer	6.01e-06	1.34e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—ocular cancer	5.95e-06	1.33e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—ocular cancer	5.89e-06	1.31e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—ocular cancer	5.76e-06	1.28e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—ocular cancer	5.63e-06	1.25e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—EP300—ocular cancer	5.51e-06	1.23e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—EP300—ocular cancer	5.37e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—EP300—ocular cancer	5.06e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—EP300—ocular cancer	5.02e-06	1.12e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—ocular cancer	4.97e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—ocular cancer	4.4e-06	9.8e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—ocular cancer	4.3e-06	9.58e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—EP300—ocular cancer	4.29e-06	9.55e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—ocular cancer	3.73e-06	8.3e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—ocular cancer	3.33e-06	7.41e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—EP300—ocular cancer	3.31e-06	7.37e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—ocular cancer	3.25e-06	7.23e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—ocular cancer	3.06e-06	6.81e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—ocular cancer	3.03e-06	6.76e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—ocular cancer	2.59e-06	5.77e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—ocular cancer	2e-06	4.46e-06	CbGpPWpGaD
